Because these complex drug resistance outcomes in cancer cells after chemotherapy or radiotherapy depend on the type of p53 mutation, the treatment of p53 with certain small-molecule drugs or peptides, and then degradation or restoration of wild-type mutant p53 activity, may contribute to increased sensitivity in the treatment of tumors containing mutant p53 (Zhou et al., 2019). Here, TP53 is linked to cancer.